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ear Editor,
I read with interest the article entitled “Association between
-reactive protein level and echocardiography assessed left
entricular function in ﬁrst ST-segment elevation myocardial
nfarctionpatientswhounderwent primary coronary intervention”
y Shacham et al. [1] in a recent issue of the Journal of Cardiology.
he authors concluded that admission of C-reactive protein (CRP)
evels is associated with echocardiographic parameters of elevated
eft ventricular (LV) ﬁlling pressure in patients with ST-segment
levation myocardial infarction (STEMI) treated with primary per-
utaneous coronary intervention (PPCI). I have some comments
bout this study.
CRP is a classic acute-phase protein that rises with a dynamic
ange of 10,000-fold within 6h and peaks at 48h [2]. Also, any
tent implantation is followedby a rapid increase inpostprocedural
RP levels [3]. In the ﬁrst paragraph of methods and patients sec-
ion of the present study, the authors mentioned CRP levels were
btained immediately following PPCI, but in the following para-
raph theymentioned blood samples for CRPwere drawn in all 173
atientswithin6hof admission to theemergency room. I think, this
onfounding sentence needs to be clariﬁed.
Another important caveat is the measurement time of echocar-
iographic parameters of the patients. The dynamic rise in CRP
evels (6–48h) can be a confounding factor on the parameters of
V diastolic function in that measured time (6–72h).
Additionally, body mass index, metabolic syndrome, diabetes
ellitus, hypertension, oral contraceptive use, physical exercise,
oderate alcohol consumption, periodontal disease, dietary pat-
erns, and smoking cause signiﬁcant variation in CRP levels [4].
In humans, statin treatment reduces levels of CRP [4]
nd the current and previous American College of Cardiology
oundation/AmericanHeart Association guidelines [5] recommend
igh-dose statin treatment early after admission in all STEMI
atients with Class 1 indication. Therefore, I wonder why Shacham
t al. [1]didnot initiate statin therapy inall patients; inotherwords,
s this a selection bias?
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reIn conclusion, adding CRP to existing variables for identifying
the patients at increased risk for long-term LV remodeling cannot
meaningfully alter clinical management.
Sincerely.
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